Active Biotech in Brief

Active Biotech develops pharmaceutical products within medical areas where the immune system is of significant importance, including cancer and inflammatory eye diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.

Active Biotech has its base in Lund, Sweden and was formed in 1998 as a spin-off from Pharmacia & Upjohn. The share is listed and traded on Nasdaq Stockholm (Small Cap). The Company has core competence in cancer and inflammatory diseases and a competent team with extensive experience in drug development from early to late-stage clinical development.

The project portfolio is composed of:

• Tasquinimod, targeted towards hematological malignancies is in clinical phase Ib/IIa for the treatment of myelofibrosis
• Laquinimod, being developed for the treatment of inflammatory eye diseases, in an eye drop formulation that has been documented to be safe and enables the distribution of laquinimod to the posterior parts of the eye in a recently completed Phase I clinical program.
• Naptumomab estafenatox (Naptumomab), licensed to NeoTX Therapeutics Ltd., is in clinical development for treatment of solid tumors. A phase Ib/II study in selected solid tumors are ongoing